DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-742/S-026

Merck and Co., Inc.
Attention: Peter Kusma
Manager, Regulatory Affairs
P. O. Box 1000, UG2CD-48
North Wales, PA 19454-1099

Dear Mr. Kusma:

Please refer to your supplemental new drug application dated and received May 15, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Stromectol™ (ivermectin), Tablets 3 mg.

We acknowledge receipt of your submission dated November 11, 2009.

This "Prior Approval" supplemental new drug application proposes to add additional information regarding ivermectin inhibition of CYP enzymes.

The **CLINICAL PHARMACOLOGY**/*Metabolism* subsection has been revised as follows (underlined text = addition, ~~strikethrough~~ text = deletion):

> ~~*Metabolism*~~
>
> *In vitro* studies using human liver microsomes and recombinant CYP450 enzymes have shown that ivermectin is primarily metabolized by CYP3A4. Depending on the *in vitro* method used, CYP2D6 and CYP2E1 were also shown to be involved in the metabolism of ivermectin but to a significantly lower extent compared to CYP3A4. The findings of *in vitro* studies using human liver microsomes suggest that clinically relevant concentrations of ivermectin do not significantly inhibit the metabolizing activities of CYP3A4, CYP2D6, CYP2C9, CYP1A2, and CYP2E1.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text for the package insert submitted on November 11, 2009.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)(1)(i)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling (text for the package insert,). For administrative purposes, please designate this submission, "SPL for approved NDA 50-742/S-026.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Hyun Son, Pharm.D., Regulatory Project Manager, at (301) 796-1600.

Sincerely,

{See appended electronic signature page}

Renata Albrecht, M.D.
Director
Division of Special Pathogen and Transplant Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Package Insert

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-50742	SUPPL-26	MERCK AND CO INC	STROMECTOL

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RENATA ALBRECHT
12/15/2009